Posaconazole: An Update of Its Clinical Use

Posaconazole (PCZ) is a relatively new addition to the azole antifungals. It has fungicidal activities against Aspergillus fumigatus, Blastomyces dermatitidis, selected Candida species, Crytopcoccus neoformans, and Trichosporon. PCZ also has fungistatic activities against Candida, Coccidioides, sele...

Full description

Bibliographic Details
Main Authors: Simon Leung, Mara N. Poulakos, Jade Machin
Format: Article
Language:English
Published: MDPI AG 2015-10-01
Series:Pharmacy
Subjects:
Online Access:http://www.mdpi.com/2226-4787/3/4/210
id doaj-abef5c0e368a4dd7a5d9d46080b40a1f
record_format Article
spelling doaj-abef5c0e368a4dd7a5d9d46080b40a1f2020-11-24T22:51:08ZengMDPI AGPharmacy2226-47872015-10-013421026810.3390/pharmacy3040210pharmacy3040210Posaconazole: An Update of Its Clinical UseSimon Leung0Mara N. Poulakos1Jade Machin2Memorial Regional Hospital, Hollywood, FL 33021, USAGregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL 33416Boca Raton Regional Hospital, Boca Raton, FL 33486, USAPosaconazole (PCZ) is a relatively new addition to the azole antifungals. It has fungicidal activities against Aspergillus fumigatus, Blastomyces dermatitidis, selected Candida species, Crytopcoccus neoformans, and Trichosporon. PCZ also has fungistatic activities against Candida, Coccidioides, selected Fusarium spp., Histoplasma, Scedosporium and Zygomycetes. In addition, combining the drug with caspofungin or amphotericin B results in a synergistic interaction against A. fumigatus, C. glabrata and C. neoformans. The absorption of PCZ suspension is enhanced when given with food, nutritional supplements, and carbonated beverages. Oral administration of PCZ in divided doses also increases its bioavailability. PCZ has a large volume of distribution and is highly protein bound (>95%). The main elimination route of PCZ is fecal. PCZ is an inhibitor of the CYP3A4 enzyme; therefore, monitoring for drug-drug interactions is warranted with other CYP3A4 substrates/inhibitors/inducers. The most common adverse effects include headache, fatigue, nausea, vomiting and elevated hepatic enzymes. PCZ, with its unique antifungal activities, expands the azole class of antifungal agents. Because of its limit in formulation, PCZ oral suspension is recommended in immunocompromised patients with functional gastrointestinaltracts who fail conventional antifungal therapies or who are suspected to have a breakthrough fungal infection. However, a delayed-release tablet formulation and intravenous (IV) injection became available in 2014, expanding the use of PCZ in other patient populations, including individuals who are unable to take oral formulations.http://www.mdpi.com/2226-4787/3/4/210posaconazolepharmacokineticspharmacodynamicscrytococcus neoformansCandidaaspergillusfusariosineutropeniacandidiasisgraft-versus-host
collection DOAJ
language English
format Article
sources DOAJ
author Simon Leung
Mara N. Poulakos
Jade Machin
spellingShingle Simon Leung
Mara N. Poulakos
Jade Machin
Posaconazole: An Update of Its Clinical Use
Pharmacy
posaconazole
pharmacokinetics
pharmacodynamics
crytococcus neoformans
Candida
aspergillus
fusariosi
neutropenia
candidiasis
graft-versus-host
author_facet Simon Leung
Mara N. Poulakos
Jade Machin
author_sort Simon Leung
title Posaconazole: An Update of Its Clinical Use
title_short Posaconazole: An Update of Its Clinical Use
title_full Posaconazole: An Update of Its Clinical Use
title_fullStr Posaconazole: An Update of Its Clinical Use
title_full_unstemmed Posaconazole: An Update of Its Clinical Use
title_sort posaconazole: an update of its clinical use
publisher MDPI AG
series Pharmacy
issn 2226-4787
publishDate 2015-10-01
description Posaconazole (PCZ) is a relatively new addition to the azole antifungals. It has fungicidal activities against Aspergillus fumigatus, Blastomyces dermatitidis, selected Candida species, Crytopcoccus neoformans, and Trichosporon. PCZ also has fungistatic activities against Candida, Coccidioides, selected Fusarium spp., Histoplasma, Scedosporium and Zygomycetes. In addition, combining the drug with caspofungin or amphotericin B results in a synergistic interaction against A. fumigatus, C. glabrata and C. neoformans. The absorption of PCZ suspension is enhanced when given with food, nutritional supplements, and carbonated beverages. Oral administration of PCZ in divided doses also increases its bioavailability. PCZ has a large volume of distribution and is highly protein bound (>95%). The main elimination route of PCZ is fecal. PCZ is an inhibitor of the CYP3A4 enzyme; therefore, monitoring for drug-drug interactions is warranted with other CYP3A4 substrates/inhibitors/inducers. The most common adverse effects include headache, fatigue, nausea, vomiting and elevated hepatic enzymes. PCZ, with its unique antifungal activities, expands the azole class of antifungal agents. Because of its limit in formulation, PCZ oral suspension is recommended in immunocompromised patients with functional gastrointestinaltracts who fail conventional antifungal therapies or who are suspected to have a breakthrough fungal infection. However, a delayed-release tablet formulation and intravenous (IV) injection became available in 2014, expanding the use of PCZ in other patient populations, including individuals who are unable to take oral formulations.
topic posaconazole
pharmacokinetics
pharmacodynamics
crytococcus neoformans
Candida
aspergillus
fusariosi
neutropenia
candidiasis
graft-versus-host
url http://www.mdpi.com/2226-4787/3/4/210
work_keys_str_mv AT simonleung posaconazoleanupdateofitsclinicaluse
AT maranpoulakos posaconazoleanupdateofitsclinicaluse
AT jademachin posaconazoleanupdateofitsclinicaluse
_version_ 1725671165881483264